Key result
Hydrocortisone significantly reduced 28-day mortality compared to placebo in patients with septic shock (RR 0.92), though it was associated with a higher incidence of superinfections.
Why the study?
The study was conducted to determine the utility of hydrocortisone in septic shock and evaluate its effect on mortality.
Does hydrocortisone reduce 28-day mortality in patients with septic shock?
Comparison
Hydrocortisone vs placebo
Design
Systematic review and meta-analysis of randomized control trials
Authors
Loading...
Hydrocortisone reduces 28-day mortality in septic shock; reinforces low-dose corticosteroid use in guidelines while highlighting superinfection risk.
Meta-Analysis (n=5,838)
Does hydrocortisone reduce 28-day mortality in patients with septic shock?
Relative Risk: 0.92 (95% CI 0.85–0.99)
Absolute Event Rate: 27.7% vs 30.1%
p-value: p=0.04
In patients with septic shock, the use of hydrocortisone significantly reduces 28-day mortality but is associated with a higher incidence of superinfections.
Siddiqui et al. (2019) conducted a meta-analysis in Septic shock (n=5,838). Hydrocortisone vs. Placebo was evaluated on Mortality at 28 days (RR 0.92, 95% CI 0.85-0.99, p=0.04). Hydrocortisone significantly reduced 28-day mortality compared to placebo in patients with septic shock (RR 0.92), though it was associated with a higher incidence of superinfections.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: